- January 10, 2020
Led by Blatt, Aligos reunites Alios team to develop functional cure for HBV
Led by a team of veterans from Alios BioPharma and Janssen, Aligos Therapeutics raised $125 million in a series B round to bring three of its HBV therapies to the clinic this year. Aligos thinks that in combination, the trio of modalities could lead to the development of a functional HBV cure under one roof.
- January 10, 2020
Nurix eligible for $2.5B in milestone payments in Sanofi deal
Nurix Therapeutics Inc. landed its second big pharma collaboration in seven months when it signed with Sanofi SA to discover, develop and commercialize a pipeline of protein degradation therapies.
- January 10, 2020
FDA Accepts IND of NK Cell Therapy for HER2 Positive Solid Tumors
Acepodia’s off-the-shelf cell therapy uses an antibody-cell conjugate to target human HER2-expressing solid tumors.
- January 10, 2020
Startup Aligos Grabs $125 Million for Drugs to Combat Hepatitis B
Aligos Therapeutics Inc., a startup headed by entrepreneurs who led venture-backed Alios BioPharma Inc. to a $1.75 billion merger with Johnson & Johnson in 2014, has raised $125 million to develop treatments for hepatitis B and other liver diseases.
- January 9, 2020
Immunotherapy takes aim at exhausted T cells
Startups attempt to revive exhausted T cells to fight solid tumors, but must strike a balance to avoid triggering adverse events.
- January 9, 2020
Small Biotech Often Better Suited to Develop Rare Disease Therapies
Gaurav Shah, MD, Chief Executive Officer & President of Rocket Pharmaceuticals explains the advantages that smaller biotech companies have in developing treatments for rare diseases. Rocket Pharmaceuticals is currently developing gene therapies for a number of rare conditions, including Fanconi anemia, Danon disease, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and infantile malignant osteopetrosis.
- January 7, 2020
Harnessing the Body’s Own Protein Waste Removal System to Drug the ‘Undruggable’
How do you catch just one kind of fish in a sea of similar fish? That’s the question being answered by researchers at Nurix, except they aren’t catching fish – they are ‘catching’ proteins in your body. Nurix is developing drugs that can specifically target one protein within the hundreds or thousands of extremely similar proteins in the body, ultimately enabling them to regulate hard-to-drug or ‘undruggable’ proteins.
- January 2, 2020
Check-Cap’s Swallowable X-Ray Pill Allows For Prep-Free Colon Cancer Screenings
It’s no secret that preparation for a colonoscopy is an uncomfortable experience. At times, the preparation can be so off-putting, that some chose to forgo the procedure altogether. For this reason, Check-Cap has created an indigestible capsule for prep-free colon cancer screening to ensure that no patient gets left behind in cancer precaution. The device is already approved in Israel and Europe, and tests for U.S. approval are currently underway.
